Luca Gianni – författare

With the current advances in chemotherapy and hormonal drugs for breast cancer, as well as in surgical techniques and procedures, a revised edition of this popular textbook has become increasingly necessary. Completely overhauling the existing material, the editors of this important work have provided a full update of the area, focusing in particul

With the current advances in chemotherapy and hormonal drugs for breast cancer, as well as in surgical techniques and procedures, a revised edition of this popular textbook has become increasingly necessary. Completely overhauling the existing material, the editors of this important work have provided a full update of the area, focusing in particul

With the current advances in chemotherapy and hormonal drugs for breast cancer, as well as in surgical techniques and procedures, a revised edition of this popular textbook has become increasingly necessary. Completely overhauling the existing material, the editors of this important work have provided a full update of the area, focusing in particular upon the topics where there has been most progress and controversy.

​Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies.Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.

​Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies.Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.

This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape.

This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape.

There can never be enough material in the public domain about cancers, and particularly breast cancer. This book adds much to the literature. It provides general information on breast cancer management and considers all new methods of diagnosis and therapy. It focuses on nuclear medicine modalities by comparing their results with other diagnostic and therapeutic approaches. The coverage provides readers with up-to-date knowledge on breast cancer as well as information on the advances in the field of diagnosis. It also details data on the development of some new modalities and provides a general overview of the available tools for breast cancer treatment.

This book provides general information on breast cancer management and considers all new methods of diagnosis and therapy. It focuses on nuclear medicine modalities by comparing their results with other diagnostic and therapeutic approaches. Coverage provides readers with up-to-date knowledge in breast cancer as well as information on the advances in the field of diagnosis. It also details data on the development of some new modalities and provides a general overview of the available tools for breast cancer treatment. The text is essential not only for nuclear medicine physicians but also for oncologists, radiologists, surgeons, and practitioners who wish to learn about the contribution of modern nuclear medicine to general breast cancer management strategies.